| Literature DB >> 21528051 |
Paolo Gionchetti1, Carlo Calabrese, Rosy Tambasco, Ramona Brugnera, Giulia Straforini, Giuseppina Liguori, Giulia Spuri Fornarini, Donatella Riso, Massimo Campieri, Fernando Rizzello.
Abstract
Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized, placebo-controlled trials, and meta-analyses when available, that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD, modifying the treatment goals. However, the large majority of patients with CD will be managed through conventional therapy, even if they are a prelude to biological therapy.Entities:
Keywords: 5-Aminosalicylic acid; 6-Mercaptopurine; Anti-tumor necrosis facto-α; Azathioprine; Biological therapies; Crohn’s disease; Sulfasalazine
Mesh:
Substances:
Year: 2011 PMID: 21528051 PMCID: PMC3080713 DOI: 10.3748/wjg.v17.i14.1797
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742